The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Notably, the benefit was consistent across all prespecified subgroups, including premenopausal status and prior chemotherapy. Secondary end points also favored giredestrant, with a 31% reduction in ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive results from the Phase 2 SUMIT-BC clinical ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...

There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...